HEADER NEUROPEPTIDE 19-JAN-05 1YL9 TITLE 3D SOLUTION STRUCTURE OF [TYR3]OCTREOTATE DERIVATIVES IN TITLE 2 DMSO COMPND MOL_ID: 1; COMPND 2 MOLECULE: [TYR3]OCTREOTATE; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: SOMATOSTATIN ANALOGUE; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: SYNTHETIC PEPTIDE WITH A TETRAMINE CHELATOR SOURCE 4 ATTACHED AT THE N-TERMINAL KEYWDS SOMATOSTATIN ANALOGUES, SANDOSTATIN, [TYR3]OCTREOTATE, KEYWDS 2 DEMOTATE, NMR CONFORMATIONAL ANALYSIS, NEUROPEPTIDE EXPDTA SOLUTION NMR NUMMDL 21 MDLTYP MINIMIZED AVERAGE AUTHOR G.A.SPYROULIAS,A.S.GALANIS,C.PETROU,D.VAHLIOTIS,P.SOTIRIOU, AUTHOR 2 A.NIKOLOPOULOU,B.NOCK,T.MAINA,P.CORDOPATIS REVDAT 2 24-FEB-09 1YL9 1 VERSN REVDAT 1 20-SEP-05 1YL9 0 JRNL AUTH G.A.SPYROULIAS,A.S.GALANIS,C.H.PETROU,D.VAHLIOTIS, JRNL AUTH 2 P.SOTIRIOU,A.NIKOLOPOULOU,B.NOCK,T.MAINA, JRNL AUTH 3 P.CORDOPATIS JRNL TITL 3D SOLUTION STRUCTURE OF [TYR3]OCTREOTATE JRNL TITL 2 DERIVATIVES IN DMSO: STRUCTURE DIFFERENTIATION OF JRNL TITL 3 PEPTIDE CORE DUE TO CHELATE GROUP ATTACHMENT AND JRNL TITL 4 BIOLOGICALLY ACTIVE CONFORMATION. JRNL REF MED.CHEM. V. 1 487 2005 JRNL REFN ISSN 1573-4064 JRNL PMID 16787334 JRNL DOI 10.2174/1573406054864089 REMARK 1 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : AMBER 5.0 REMARK 3 AUTHORS : PEARLMAN, D.A.; CASE, D.A.; CALDWELL, J.W.; REMARK 3 ROSS, W.S.; CHEATHAM, T.E.; FERGUSON, D.M.; REMARK 3 SEIBEL, G.L.; SINGH, U.C.; WEINER, P.K.; REMARK 3 KOLLMAN, P.A. REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE MODELS ARE CALCULATED USING 155 REMARK 3 NOE-DERIVED CONSTRAINTS, FROM NOESY SPECTRA ACQUIRED USING 400 REMARK 3 MS OF MIXING TIME REMARK 4 REMARK 4 1YL9 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 10-FEB-05. REMARK 100 THE RCSB ID CODE IS RCSB031645. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : NULL REMARK 210 IONIC STRENGTH : NULL REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 2-3MM PEPTIDE; DMSO REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D NOESY, 2D TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 400 MHZ REMARK 210 SPECTROMETER MODEL : DPX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : XWINNMR 2.6, XEASY 1.3, DYANA REMARK 210 1.5 REMARK 210 METHOD USED : SIMULATED ANNEALING, TORSION REMARK 210 ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 400 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 21 REMARK 210 CONFORMERS, SELECTION CRITERIA : TARGET FUNCTION REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: THIS STRUCTURE WAS DETERMINED USING STANDARD 2D REMARK 210 HOMONUCLEAR TECHNIQUES REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 CYS A 8 72.99 24.39 REMARK 500 3 CYS A 8 67.52 39.75 REMARK 500 4 CYS A 8 70.48 41.38 REMARK 500 5 CYS A 8 66.41 35.72 REMARK 500 6 CYS A 8 60.09 39.99 REMARK 500 7 CYS A 8 69.17 23.70 REMARK 500 8 CYS A 8 64.94 34.85 REMARK 500 9 CYS A 8 71.99 31.99 REMARK 500 10 CYS A 8 71.01 32.28 REMARK 500 11 CYS A 8 71.22 31.53 REMARK 500 12 CYS A 8 71.97 26.21 REMARK 500 13 CYS A 8 69.91 33.25 REMARK 500 15 CYS A 8 67.35 26.31 REMARK 500 16 CYS A 8 72.07 32.72 REMARK 500 17 CYS A 8 65.47 33.85 REMARK 500 18 CYS A 8 61.69 35.84 REMARK 500 19 CYS A 8 68.58 25.52 REMARK 500 20 CYS A 8 71.85 31.54 REMARK 500 21 CYS A 8 70.06 38.05 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CH4 A 0 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1SOC RELATED DB: PDB REMARK 900 SANDOSTATIN (OCTREOTIDE) PEPTIDE REMARK 900 RELATED ID: 2SOC RELATED DB: PDB REMARK 900 SANDOSTATIN (OCTREOTIDE) PEPTIDE REMARK 900 RELATED ID: 1YL8 RELATED DB: PDB DBREF 1YL9 A 2 9 PDB 1YL9 1YL9 2 9 SEQRES 1 A 8 DPN CYS TYR DTR LYS THR CYS THR HET DPN A 2 20 HET DTR A 5 24 HET CH4 A 0 32 HETNAM DPN D-PHENYLALANINE HETNAM DTR D-TRYPTOPHAN HETNAM CH4 3-[(2-AMINOETHYL)AMINO]-2-{[(2-AMINOETHYL) HETNAM 2 CH4 AMINO]METHYL}PROPANAL FORMUL 1 DPN C9 H11 N O2 FORMUL 1 DTR C11 H12 N2 O2 FORMUL 2 CH4 C8 H20 N4 O SSBOND 1 CYS A 3 CYS A 8 1555 1555 2.05 LINK N DPN A 2 C CH4 A 0 1555 1555 1.34 LINK C DPN A 2 N CYS A 3 1555 1555 1.33 LINK C TYR A 4 N DTR A 5 1555 1555 1.33 LINK C DTR A 5 N LYS A 6 1555 1555 1.34 SITE 1 AC1 3 DPN A 2 CYS A 3 THR A 9 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL MASTER 101 0 3 0 0 0 1 6 0 0 0 1 END